• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Lamivudine Zidovudine Teva
    / Abic


    Active Ingredient *
    Lamivudine 150 mg
    Zidovudine 300 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    60 X 150/300mg

    46819

    Related information


    Dosage

    May be administered with or without food.
    Adults and adolescents weighing at least 30 kg: 1 tablet twice daily. Children weighing between 21 kg and 30 kg : one-half tablet taken in the morning and one whole tablet taken in the evening.
    Children weighing from 14 kg to 21 kg : one-half tablet taken twice daily.
    Elderly : No specific data are available, however special care is advised in this age group due to age associated changes such as the decrease in renal function and alteration of haematological parameters.
    Renal impairment: Dosage adjustment is required in patients with a creatinine clearance of less than 50 ml/min. It is therefore recommended that separate preparations of lamivudine and zidovudine should be administered to these patients.
    Hepatic impairment: Dosage adjustments may be necessary in patients. It is therefore recommended that separate preparations of lamivudine and zidovudine should be administered to patients with severe hepatic impairment.
    Dosage adjustments in patients with haematological adverse reactions: Dosage adjustment may be necessary if the haemoglobin level falls below 9 g/dl or 5.59 mmol/l or the neutrophil count falls below 1.0 x 109/l. Separate preparations of zidovudine and lamivudine should be used.
    See prescribing information for further information.


    Indications

    Antiretroviral combination therapy for the treatment of HIV infected adults and adolescents over the age of 12 years.


    Contra-Indications

    Patients with known hypersensitivity to lamivudine, zidovudine or to any other ingredient of the preparation. Patients with abnormally low neutrophil counts (less than 0.75 x 109/l), or abnormally low haemoglobin levels (less than 7.5g/dl or 4.65 mmol/l).


    Special Precautions

    See prescribing information for further information.


    Side Effects

    See prescribing information for further information.


    Manufacturer
    Teva Hungary
    CLOSE